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The human microbiome is the collection of bacteria, viruses, and fungi that live on and in the human organism’s
skin, mucosa, and intestinal tract. Re-examining commonly accepted ethical standards from the perspective of this
new area of research provides an opportunity to reassess our current thinking about research regulations as well as
the importance of some principles and distinctions. In this commentary, I explain ethical issues illuminated by
research on the human microbiome related to personal identity, privacy, property, research ethics, public health,
and biobanks.
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Background
The cohabitation of the human genome and the ge-
nomes of the bacteria and viruses that occupy our skin,
mucous membranes, intestinal tract, and other parts of
our bodies together make up the microbiome. In 2007,
the National Institute of Health launched the Human
Microbiome Project to utilize technological advances to
characterize the microbial communities that inhabit the
human body and explore the relationships between the
microbiota and their human hosts, including the effect
that they may have on human health and disease, devel-
opment, physiology, immunity, and nutrition.
Learning about the microbiome will change how
medicine is practiced. It may also have implications
for our social and legal systems and for how we con-
ceive the ethics of medicine and biomedical research.
Therefore, it is important to identify the ethical, legal,
and social implications raised by human microbiome
research in order to advise both the scientists en-
gaged in the work and members of society who will
participate in studies and live with the consequences .
Addressing issues from the vantage point of microbiome
research provides a fresh perspective on who we are, our
place in the world, and our responsibilities to one another.
For example, research on the human microbiome calls for
a paradigm shift from thinking about germs as enemies
that must be hunted and destroyed to thinking about
achieving a healthy microbiotic environment around and
within us. Further, clinicians and investigators will be
expanding their focus from diagnosing individual genetic
anomalies to developing an understanding of the human
genome and its interactions with the microbiome [1–3].
In addition, studies to advance personalized medicine will
require broad public participation to provide sufficient
material for biobanks and sample banks rather than a
small sample of people with a target condition. Although
personhood and identity have never been simple concepts,
as we learn more about ourselves as an amalgam of us
and the microbes that live on us and within us, we will re-
think our concepts of personal identity and normalcy.
Thus, in numerous ways, learning about the microbiome
may shift the moral perspective from a focus on individual
rights and liberties toward a community perspective that
values solidarity.
Personal identity
“I” used to be a simple term, and everyone knew what “I”
meant. Now, in light of what we are learning from science,
“I” refers to me as a moral agent, and the subject of my
consciousness, and my genotype, and my phenotype, and
my microbiome comprised of critters that are not me,
many of which come and go. In different contexts, differ-
ent concepts of “me” are relevant. Ethically, only some
humans are moral persons, because only some can be held
responsible for their actions (e.g., young children cannot
be). As a victim of disease, my body is my identity. As a
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vector of disease, my microbiome is my identity. The
microbiome has an impact on the health of the human
organism, but its effects are determined, in part, by the
combined characteristics of the microbes that comprise it.
A particular species of microbe might have positive effects
in one human and negative effects in another. These dif-
ferences will complicate efforts to define what is “normal.”
Although personhood and identity have never been simple
concepts, as we come to see ourselves as an amalgam of
us and them, we will have to rethink concepts of personal
identity, normalcy, and what they imply [4, 5].
Our understanding of the human microbiome and its
interaction with the human body also has implications
for how we conceptualize both personhood and personal
identity. Personhood is usually defined in terms of essen-
tial and distinguishing characteristics. Thus, if genes,
diet, and microbes distinguish our susceptibility and re-
sistance to disease and responsiveness to treatments,
they may all be part of our identity [6, 7]. Furthermore,
each individual’s microbiome is unique [8]. In that sense,
the microbiome may be incorporated into how we define
ourselves as persons.
Privacy
For the most part, the borders of privacy conform to
physical boundaries. They coincide with personal
enclosed spaces such as my body, my home, behind the
closed door of my bedroom, inside my own diary, and
inside my own thoughts. With few exceptions, no one
may enter my private domain without my permission,
and governmental intrusions require robust justification.
Confidentiality is different from privacy [9]. Confiden-
tiality is an important professional responsibility for cli-
nicians and some other professionals (e.g., lawyers,
accountants, priests). In these professions, an artificial
space is created within which information is safeguarded.
Within those boundaries, information disclosed by those
seeking professional services may be shared in order to
promote the client’s interests. Outside of those boundar-
ies, disclosed information may be divulged only with the
client’s permission. Thus, in medicine, patients expect
their medical history, diagnosis, and prognosis only to
be shared among the health professionals who need it
for providing care. Beyond that, patients reasonably ex-
pect their information not to be divulged. The assurance
of confidentiality is critical for the practice of medicine
because it allows patients to freely share information.
Although the concepts of “confidentiality” and “priv-
acy” are frequently conflated and the distinctions elided,
the difference may be critical in work on the human
microbiome. When we examine privacy and confidenti-
ality from the perspective of research on the microbiome
we will have to consider which information should be
protected and why. Many research ethics discussions
come down strongly on the side of treating research
samples with privacy protections, but at this point it is
appropriate to ask whether strict limitations on sharing
samples are reasonable.
Learning about the human microbiome will raise add-
itional privacy questions with important implications in
matters of personal liberty. Approximately 95 % of my
feces are microbiome, and my microbiome tells the story
of where I have been and with whom I have associated.
Should law enforcement agents have access to my
microbiome in the same way that they are allowed to
collect my fingerprint trail?
Property
In the philosophical literature, we see radically different
views on property, and the ethical, legal, and social ques-
tions about who owns what. These controversies extend to
deposits in biobanks and sample banks [10, 11]. Do we have
property rights in our microbiome because our body is its
host? Under some circumstances the government may
mandate invasions into (e.g., vaccinations) and uses of (e.g.,
compelled military service) our bodies. May government
rightfully demand that we contribute genome or micro-
biome samples to research or public health activities?
When knowledge from a microbiome study has commer-
cial value, who should reap the profits? If someone’s micro-
biome is unique and valuable, who owns it? Although we
have not yet seen lawsuits involving the human micro-
biome, there have recently been a few legal rulings related
to biological samples and genetic research that are relevant
to the human microbiome.
Human subject research
According to popular accounts of research ethics history
[12, 13], the development of research standards and regu-
lations begins with the Nuremberg Code, followed by the
World Medical Association’s Helsinki Agreement [14, 15].
The second half of the twentieth century was also the
period of the assertion of civil rights, women’s rights, and
rights of people with disabilities, all of which are move-
ments argued in terms of autonomy. It is no surprise,
therefore, that The Belmont Report and the Common
Rule, the US research regulations that it produced, as well
as the International Ethical Guidelines for Biomedical Re-
search Involving Human Subjects are informed by that
concept and expressed in terms of respect for persons [16,
17]. That commitment to autonomy gives primacy to in-
formed consent and privacy in contemporary research
ethics.
In this tradition of research ethics, the authority to
employ human subjects in studies derives from the par-
ticipant’s informed consent. The decision to participate
in a study is taken as endorsement of the research goals
and as free acceptance of the burdens and risks involved
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as being reasonable under the circumstances. In keeping
with the twentieth century’s focus on autonomy, a good
deal of the NIH Human Genome Project work on the
ethical, legal, and social implications of research on the
human genome has focused on individual liberty- and
autonomy-related human rights concerns.
At the same time, the literature on the ethical, legal,
and social implications of the human genome study has
largely overlooked what John Gray has described as the
other face of social contract theory, the obligations of the
participant [18]. Yet, at this stage in the development of
the science, researchers have expanded their focus from
the diagnosis of individual genetic anomalies to the
broader issues of understanding the human genome and
its interactions with the microbiome, for example, in
diabetes and inflammatory bowel diseases. As many have
noted, studies to advance personalized medicine will re-
quire broad participation to provide the material for bio-
banks and sample banks [19, 20]. These efforts will raise
issues of whether we should all contribute to the enter-
prise. In that some genetic and microbiome research is
supported by public funds, we all contribute our finan-
cing to the efforts. Should we also contribute bits of our-
selves, our genomes, and our microbiomes? If we expect
to benefit from what is learned, but are unwilling to par-
ticipate, will we be free-riders on the altruism of others?
Will we be treating others unjustly? Answering these
questions will require clarification of the individual re-
sponsibilities of members of society.
Public health
Similar issues arise in public health and public health re-
search [21, 22]. Because the microbiome is a factor in
some infectious diseases, protecting public health re-
quires disease surveillance and tracking. Data collection
on disease outbreaks, births, and deaths is and will be
critical in the design and implementation of effective
disease prevention, outbreak control, and disaster re-
sponse. Effective public health measures are based on
data, but gathering personal information in an emer-
gency may not allow for prior Institutional Review Board
assessment or informed consent [23].
Most clinical research exposes only individual subjects
to risks and harms. Yet, as research on the human micro-
biome leads to studies of prebiotic, probiotic (bacterial),
and phage (viral) therapies, the risks to the public as well
as research subjects will be relevant considerations. When
we contemplate altering the human microbiome by indu-
cing changes in naturally occurring collections of mi-
crobes, we need to be cognizant of the fact that people are
both vectors and victims of disease [24, 25]. Furthermore,
microbial agents that are beneficial to some humans may
be toxic to other humans and other organisms. Addition-
ally, because microbes that may benefit some may be
communicated to others and harm them, we will have to
evaluate and assess the complex potential public health
risks associated with studies of conditions such as obesity
and asthma [26].
Biobanks
It is easy to appreciate that we all want to avoid diseases
and their burdens and, when these cannot be avoided,
we expect efficient and effective means to overcome
them. Having such treatments available will require sig-
nificant scientific advances that necessitate basic science
and translational research involving biobanking, sample
banking, and human subject research. For example, the
goal of advancing the treatment of cancer through per-
sonalized medicine requires research on samples from a
large number of individuals with different cancer types
[27–29]. The emerging need for further research and
more general cooperation in research raises questions
about the rules and governance of biobank and sample
banks. Who should be given access to the biological
samples, which information should be shared, which
projects should the samples support, and who should
make these decisions?
Conclusion
The use of technology employing knowledge of the hu-
man microbiome is just getting started and is not yet
widely applied. Nevertheless, it is important to consider
the ethical issues early on so that we may try to avoid at
least those pitfalls that can be identified now rather than
waiting for disasters to occur and then trying to cobble
together hasty responses. Fresh consideration of these is-
sues by the biomedical research community, eschewing
both exaggeration of the risks and ignoring real issues,
will require both clear thinking and courage.
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